SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-184817
Filing Date
2024-07-25
Accepted
2024-07-25 16:02:59
Documents
13
Period of Report
2024-07-19
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d868248d8k.htm   iXBRL 8-K 23000
  Complete submission text file 0001193125-24-184817.txt   148653

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tnya-20240719.xsd EX-101.SCH 2884
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tnya-20240719_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tnya-20240719_pre.xml EX-101.PRE 11730
15 EXTRACTED XBRL INSTANCE DOCUMENT d868248d8k_htm.xml XML 3789
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

IRS No.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 241141997
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)